Goldman Sachs just issued a report saying that the non-approval MNTA received in Nov 2007 relating to Lovenox immunogenicity was a Minor Deficiency letter. This is contrary to my understanding of what happened, but I thought it was worth mentioning.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.